Contrast agent BR1 clinical trials
A product of Sulfur Hexafluoride; its studies count on that page too.
How each study uses contrast agent BR1 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the contrast agent BR1 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 10 Oct 2014 · LUMASON · NDA 203684 (FDA, Drugs@FDA; as Sulfur Hexafluoride)
- European Union
- 26 Mar 2001 · SonoVue · EMEA/H/C/000303 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 10
Bracco Diagnostics, Inc (3) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Enrico Ammirati (1) · Société Française d'Endoscopie Digestive (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · NaviFUS Corporation (1) · Central Hospital, Nancy, France (1) · Umeå University (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- A dosage form of Sulfur Hexafluoride source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test contrast agent BR1, phase 3 first.
Studies
Open first, then newest update. How each study uses contrast agent BR1 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme PatientsRecruitingPhase 3NaviFUS CorporationNCT06496971Written as MicrobubbleHow we know
- Study of Placental Vascularization Using Contrast UltrasoundRecruitingPhase 3Central Hospital, Nancy, FranceNCT06497959Written as SonoVueHow we know
- Liver Cirrhosis Complicated by Clinically Significant Portal HypertensionNot yet recruitingNot applicableFondazione Policlinico Universitario Agostino Gemelli IRCCSNCT07365709Written as SonoVueHow we know
- Comparing SonoVue With Sonazoid Using CEUS-LIRADS in HCCStatus unknownPhase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT04006275Written as Sonovue and SonazoidHow we know
- Multiparametric Ultrasound Imaging in Prostate CancerStatus unknownNot applicableAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT03101176Written as SonoVueHow we know
- SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion CharacterizationCompletedPhase 3Bracco Diagnostics, IncNCT00829413Written as SonoVue®How we know
- Contrast Enhanced Sonothrombolysis and Sonolysis in Stroke - a Swedish Study (CE-5S)TerminatedPhase 3Umeå UniversityNCT03290053Written as SonoVueHow we know
- IMaging Della PLAcca CarotideaCompletedPhase 3Enrico AmmiratiNCT03333330Written as Visipaque 320 and SonoVueHow we know
- KVUS at Neoadjuvant CTx of Breast CancerStatus unknownPhase 3RWTH Aachen UniversityNCT03385200Written as SonoVueHow we know
- SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion CharacterizationCompletedPhase 3Bracco Diagnostics, IncNCT00788697Written as SonoVue-enhanced ultrasoundHow we know
- Safety of SonoVue on Pulmonary HemodynamicsCompletedPhase 2Bracco Diagnostics, IncNCT01306292Written as SonoVueHow we know
- Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate CancerTerminatedNot applicableAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT01481441Written as SonoVueHow we know
- Breast Lesions Characterization on Contrast Enhanced Ultrasound With Histopathological CorrelationStatus unknownNot applicableRambam Health Care CampusNCT02177045Written as Sonovue, BraccoHow we know
- Contrast-harmonic Endoscopic Ultrasound (CH-EUS) for the Diagnosis of Pancreatic AdenocarcinomaCompletedNot applicableSociété Française d'Endoscopie DigestiveNCT01765036Written as SonoVue®How we know
Given beside what is tested · 2 — contrast agent BR1 is usual care or a partner of the new treatment
- Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal AdenocarcinomaCompletedPhase 2St. Olavs HospitalNCT04146441Written as SonoVueHow we know
- Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal CancerCompletedPhase 1/2St. Olavs HospitalNCT03477019Written as SonoVueHow we know
As the comparator · 1 — what is tested is compared with contrast agent BR1
Codes
What other systems call contrast agent BR1 · ClinicalTrials.gg INT004309
- MeSH (NLM) C420843contrast agent BR1One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C420843 | contrast agent BR1 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.